aldosterone
-
Mineralys in Radnor Raises $192M for Blood Pressure Drug
A public stock offering from Mineralys Therapeutics of Radnor netted $192 million for the company’s development of a new blood pressure drug candidate, lorundrostat, writes…
-
Radnor Biopharma Firm Looks at Hormone Targeting to Treat Hypertension
Mineralys Therapeutics in Radnor is on its way to developing a drug that will selectively treat hypertension, writes Laura Brzyski for Philadelphia Magazine. Mineralys Therapeutics…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
